Innovative Medicines Initiative

With support from the Innovative Medicines Initiative, you will be able to conduct international research for the development of new and efficient medical treatments. The initiative aims at strengthening Europe’s competitiveness through collaborations between stakeholders such as the biotech and pharma industry, governmental institutions, patient associations, and research institutions. The IMI offers funding opportunities for large companies as well as SMEs.

The Innovative Medicines Initiative is supporting a number of research topics. Overall, IMI aims to deliver:

  • A 30% better success rate in clinical trials of priority medicines identified by the WHO

  • Clinical proof of concept in immunological, respiratory, neurological and neurodegenerative diseases in just five years

  • New and approved diagnostic markers for four of these diseases and at least two new medicines which could either be new antibiotics or new therapies for Alzheimer’s disease

For 2014-2024, the IMI has a budget of 3.3 billion euro. It is financed by the EU and the industry organisation EFPIA.

Below are the upcoming deadlines for Innovative Medicines Initiative. Expect 1-2 months for the proposal writing process.

IMI - Call 8

Deadline: March 16, 2017

The topic of this call is: Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks.

This call is the second call under the Ebola+ programme. It provides an opportunity to capture emerging scientific advances and to progress those rapidly into health care interventions. Projects funded under this call should ensure fast development, uptake and/or wide deployment of sustainable innovative solutions that will result in an increased readiness to respond to future outbreaks.

IMI - Call 10

Deadline: March 28, 2017

IMI has launched its 10th Call for proposals under the IMI2 programme, with the following topics:

  • Topic 1: Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials

  • Topic 2: How big data could support better diagnosis and treatment outcomes for prostate cancer (part of the Big Data for Better Outcomes programme)

  • Topic 3: Improving the care of patients suffering from acute or chronic pain (this topic includes three subtopics on patient reported outcomes; biomarkers; and chronic pelvic pain)

  • Topic 4: Creation of a pan-European paediatric clinical trials network

  • Topic 5: Biomanufacturing 2020: development of innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes

  • Topic 6: Unlocking the solute carrier gene-family for effective new therapies (unlock SLCs)

  • Topic 7: Patient perspectives in medicines lifecycle

  • Topic 8: Personalised medicine approaches in autism spectrum disorders

 

IMI - Call 8

Deadline: September 14, 2017

The topic of this call is: Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks.

This call is the second call under the Ebola+ programme. It provides an opportunity to capture emerging scientific advances and to progress those rapidly into health care interventions. Projects funded under this call should ensure fast development, uptake and/or wide deployment of sustainable innovative solutions that will result in an increased readiness to respond to future outbreaks.

Ependysis Business Consultants can prepare you in the submission of the investment file, as well as to help you arrange the partners of the project. 

  • Ependysis@Facebook
  • Ependysis@Twitter
  • Ependysis@Google+
  • Ependysis@YouTube
  • Ependysis@Pinterest
Clients
Show More

© 2016 by Ependysis Business Consultants